Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 14.3%

Oncolytics Biotech, Inc. (NASDAQ:ONCY)’s stock price rose 14.3% on Monday . The stock traded as high as $1.28 and last traded at $1.28, approximately 1,755,878 shares traded hands during trading. An increase of 671% from the average daily volume of 227,663 shares. The stock had previously closed at $1.12.

ONCY has been the topic of several recent research reports. Zacks Investment Research upgraded Oncolytics Biotech from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Saturday, November 16th. Roth Capital initiated coverage on Oncolytics Biotech in a report on Wednesday, September 4th. They set a “buy” rating and a $7.00 price target on the stock. Finally, ValuEngine lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th.

The company has a fifty day moving average of $0.85 and a two-hundred day moving average of $1.14. The company has a market cap of $28.01 million, a PE ratio of -1.56 and a beta of 2.14. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.78 and a current ratio of 3.78.

An institutional investor recently bought a new position in Oncolytics Biotech stock. Verition Fund Management LLC bought a new position in Oncolytics Biotech, Inc. (NASDAQ:ONCY) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 408,838 shares of the company’s stock, valued at approximately $695,000. Verition Fund Management LLC owned 2.01% of Oncolytics Biotech as of its most recent SEC filing. 1.59% of the stock is owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile (NASDAQ:ONCY)

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Recommended Story: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.